Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions

Inclusion Criteria: * Human subjects aged between 18 and 45 years (including both) * Subjects'weight within the normal range according to normal values for the Body Mass Index (18.5 to 24.9kgm2)with minimum of 50 kg weight. * Subjects with normal health as determined by personal medical history clinical examination and laboratory examinations within the clinically acceptable normal range. * Subjects having normal 12-lead electrocardiogram (ECG). * Subjects having normal chest X-Ray (P/A view). * Have a negative urine screen for drugs of abuse (including amphetamines,barbiturates, benzodiazepines, marijuana, cocaine, and morphine). * Have negative alcohol breath test. * Subjects willing to adhere to the protocol requirements and to provide written informed consent. Exclusion Criteria: Subjects will be excluded from the study, if they meet any of the following criteria: * Hypersensitivity to Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride or related drugs. * History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder. * History or presence of significant alcoholism or drug abuse in the past one year. * History or presence of significant smoking (more than 10 cigarettes or beedi's/day). * History or presence of significant asthma, urticaria or other allergic reactions. * History or presence of significant gastric and/or duodenal ulceration. * History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour. * History or presence of cancer. * Difficulty with donating blood. * Difficulty in swallowing solids like tablets or capsules. * Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg. * Diastolic blood pressure less than SO mm Hg or more than 90 mm Hg. * Pulse rate less than 50/minute or more than 100/minute. * Oral temperature less than 95°F or more than 98.5°F. * Respiratory rate less than 12/minute or more than 20/minute * SUbjects who have used any prescription medication, within 14 days of period 01 dosing or OTC medication within 14 days of period 01 dosing. * Major illness during 3 months before screening. * Participation in a drug research study within past 3 months. * Donation of blood in the past 3 months before screening. * Subjects who have consumed xanthine-containing products (including caffeine, theobromines, etc.) within 48 hours prior to period 01 dosing. * Subjects who have consumed food or beverages containing grapefruit or pomelo within 14 days prior to period 01 dosing.